SciELO - Scientific Electronic Library Online

 
vol.131 número3Susceptibilidad antifúngica de levaduras mediante Etest ®: Comparación de 3 mediosTransección traumática aguda de la aorta torácica: Tratamiento endovascular índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

Compartilhar


Revista médica de Chile

versão impressa ISSN 0034-9887

Resumo

RODRIGUEZ G, Cristián et al. X-linked hyper-IGM syndrome associated to sclerosing cholangitis and gallbladder cancer. Rev. méd. Chile [online]. 2003, vol.131, n.3, pp.303-308. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872003000300009.

We report a 11 years old male diagnosed as a X-linked hyper-IgM syndrome that presented with recurrent infections and sclerosing cholangitis and later developed a gallbladder cancer. Immunological evaluation showed decreased levels of serum IgG and IgA with elevated levels of IgM. Study of CD40 ligand expression on mitogen activated peripheral blood mononuclear cells revealed total absence of this marker on T lymphocytes. Molecular analysis detected, in the patient and his mother, a nonsense mutation in exon 1 of the transmembrane segment of the CD40 ligand. He also presented elevation of alkaline phosphatases and mild elevation of liver enzymes. Liver biopsy demonstrated the presence of idiopathic sclerosing cholangitis. The patient was started on monthly IVIG therapy at 400 mg/kg, as well as ursodeoxycholic acid and vitamin E, with normalization of his IgG and IgM levels a decrease in the incidence of infections and normalization of liver function. Three years after diagnosis, we detected the presence of polyps inside the gallbladder that were reported at biopsy as adenocarcinoma. He underwent hepatic bisegmentectomy (VI B-V) and local lymphadenectomy (Rev Méd Chile 2003; 131: 303-8).

Palavras-chave : Cholangitis, Sclerosing; Gallbladder, neoplasms; IgM.

        · texto em Espanhol

 

Creative Commons License Todo o conteúdo deste periódico, exceto onde está identificado, está licenciado sob uma Licença Creative Commons